Provided by Tiger Trade Technology Pte. Ltd.

Immuneering Corp

4.10
-0.0350-0.85%
Post-market: 4.110.0150+0.37%19:30 EDT
Volume:596.82K
Turnover:2.47M
Market Cap:264.41M
PE:-4.18
High:4.23
Open:4.16
Low:4.09
Close:4.13
52wk High:8.48
52wk Low:3.86
Shares:64.57M
Float Shares:49.21M
Volume Ratio:1.05
T/O Rate:1.21%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9796
EPS(LYR):-1.2729
ROE:-52.15%
ROA:-32.77%
PB:1.39
PE(LYR):-3.22

Loading ...

Immuneering Q1 FY26 net loss narrows to $13.5 million

Reuters
·
May 15

Immuneering Q1 EPS $(0.21) Beats $(0.26) Estimate

Benzinga Earnings
·
May 15

Immuneering Corp - Ends Q1 2026 With $198.6 Mln in Cash and Securities; Runway Into 2029

THOMSON REUTERS
·
May 15

Immuneering Corporation Q1 Net Income USD -13.5 Million VS. Ibes Estimate USD -17.3 Million

THOMSON REUTERS
·
May 15

Press Release: Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates

Dow Jones
·
May 15

Immuneering’s Phase 3 Pancreatic Cancer Trial Puts Atebimetinib in the Spotlight for IMRX Investors

TIPRANKS
·
May 08

Immuneering announces updated data from Phase 2a trial for atebimetinib

TIPRANKS
·
Apr 22

Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting

GlobeNewswire
·
Apr 22

Analysts Offer Insights on Healthcare Companies: Immuneering (IMRX) and McKesson (MCK)

TIPRANKS
·
Apr 21

Immuneering announces annual shareholder meeting webcast

Reuters
·
Apr 21

Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond

GlobeNewswire
·
Apr 20

Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Immuneering (IMRX) and Maze Therapeutics, Inc. (MAZE)

TIPRANKS
·
Apr 14

Immuneering CEO to join Needham Virtual Healthcare Conference fireside chat

Reuters
·
Apr 07